6 assets in Subcutaneous Panniculitis-Like T-Cell Lymphoma

Therapeutic assets addressing Subcutaneous Panniculitis-Like T-Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Subcutaneous Panniculitis-Like T-Cell Lymphoma	National Cancer Institute (NCI)	P4	BB (68)
Pembrolizumab Subcutaneous Panniculitis-Like T-Cell Lymphoma	Northwestern University	P2	B (60)
Immunoglobulin G1, Anti-(Human/Macaca Fascicularis/Macaca Mulatta Killer Cell Lectin-Like Receptor Klrd1) (Human Monoclonal Dr-01 ?1-Chain), Disulfide With Human Monoclonal Dr-01 ?-Chain, Dimer Subcutaneous Panniculitis-Like T-Cell Lymphoma	Dren Bio	P1/2	CCC (48)
Pralatrexate Subcutaneous Panniculitis-Like T-Cell Lymphoma	City of Hope Medical Center	P1/2	CCC (48)
Autologous Ccr4 Car T Cells Subcutaneous Panniculitis-Like T-Cell Lymphoma	National Cancer Institute (NCI)	P1	CC (43)
Fludarabine Subcutaneous Panniculitis-Like T-Cell Lymphoma	National Cancer Institute (NCI)	P1	CC (43)